EU antitrust regulators resume foreign aid probe into ADNOC's Covestro deal

EU antitrust regulators have resumed their foreign aid probe into Abu Dhabi state oil giant ADNOC's 14.7 billion euro acquisition of German chemicals company Covestro, setting a new decision deadline of July 28 after the companies provided requested information. This scrutiny, distinct from the merger approval ADNOC previously secured, falls under the EU's Foreign Subsidies Regulation, which targets unfair foreign state aid and could necessitate concessions for deal clearance.

Analysis

The resumption of the European Union's antitrust probe into Abu Dhabi National Oil Company's (ADNOC) proposed €14.7 billion acquisition of Covestro introduces a significant regulatory hurdle under the new Foreign Subsidies Regulation (FSR). This investigation is distinct from the standard merger review, which ADNOC had already cleared in May, and specifically targets potential unfair advantages derived from foreign state aid. The European Commission has set a new decision deadline of July 28, creating a near-term catalyst and a period of heightened uncertainty for the transaction's completion. The primary risk stemming from this FSR review, which is reflected in the mildly negative sentiment signal, is the potential for mandated concessions required to offset perceived state support, which could alter the deal's economics or timeline.

Key Decisions for Investors

• Investors should closely monitor communications from EU regulators leading up to the new July 28 decision deadline, as this date represents a significant catalyst for the deal's progression.
• It is crucial to assess the risk of either a deal blockage or the imposition of material concessions under the Foreign Subsidies Regulation, as this introduces a layer of uncertainty beyond standard merger arbitrage.
• For those holding or considering a position in Covestro, recognize that the stock's performance until the deadline will be heavily influenced by sentiment around the probability of a favorable regulatory outcome.